Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (7)
  • Open Access

    ARTICLE

    ETV4-Mediated PD-L1 Upregulation Promotes Immune Evasion and Predicts Poor Immunotherapy Response in Melanoma

    Tao Zhu1, Taofeng Wei1, Mingdong Yang1, Junjun Xu1, Huifang Jiang1, Wei He1, Juyan Zheng2,*, Haibin Dai1,*

    Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070180 - 30 December 2025

    Abstract Background: Aberrant expression of transcription factors (TFs) is a key mechanism mediating tumor immune escape and therapeutic resistance. The involvement of E26 transformation-specific (ETS) family of TFs in immune regulation is not fully understood. The study aimed to elucidate the function of E-twenty-six variant 4 (ETV4) in tumor immune evasion and its potential as a predictive biomarker for immunotherapy in melanoma. Methods: The expression patterns of ETS family TFs were analyzed in melanoma and hepatocellular carcinoma (HCC). Single-cell RNA sequencing (scRNA-seq) was used to dissect the cellular expression and function of ETV4 in the tumor… More >

  • Open Access

    ARTICLE

    RFX1 Regulates Immune Microenvironment and Predicts Immunotherapy Response in Colon Cancer: A Multi-Omics and Clinical Analysis

    Zhujiang Dai1,2,#, Xiaoyong Ge1,2,#, Wenbo Tang1,2, Chen-Ying Liu1,2, Yun Liu1,2,*, Zhongchuan Wang1,2,*

    Oncology Research, Vol.33, No.12, pp. 4113-4143, 2025, DOI:10.32604/or.2025.068473 - 27 November 2025

    Abstract Objective: The plastic role of regulatory factor X1 (RFX1) in colon cancer progression and its impact on the tumor microenvironment remain poorly understood. The study aimed to clarify the molecular and clinical role of RFX1 in colon cancer. Methods: We classified colon cancers into subgroups with high and low RFX1 expression and characterized their immune profiles, mutational profiles, cancer immunotherapy and drug sensitivity. By combining RFX1 expression with persistent tumor mutational burden, we proposed a novel nomogram clinical prediction model and validated its predictive performance, and the correlation between high expression and poor prognosis. Results: Compared… More > Graphic Abstract

    RFX1 Regulates Immune Microenvironment and Predicts Immunotherapy Response in Colon Cancer: A Multi-Omics and Clinical Analysis

  • Open Access

    ARTICLE

    Integrating Spatial Multi-Omics and Machine Learning to Unravel the Role of PANoptosis in Bladder Cancer Prognosis and Immunotherapy Response

    Liangju Peng1,2, Tingting Cai1,2, Peihang Xu1,2, Cong Chen3, Qingzhi Xiang1,2, Yiping Zhu1,2, Dingwei Ye1,2,*, Yijun Shen1,2,*

    Oncology Research, Vol.33, No.9, pp. 2463-2489, 2025, DOI:10.32604/or.2025.064331 - 28 August 2025

    Abstract Background: Studies have reported the special value of PANoptosis in cancer, but there is no study on the prognostic and therapeutic effects of PANoptosis in bladder cancer (BLCA). This study aimed to explore the role of PANoptosis in BLCA heterogeneity and its impact on clinical outcomes and immunotherapy response while establishing a robust prognostic model based on PANoptosis-related features. Methods: Gene expression profiles and clinical data were collected from public databases. Spatial heterogeneity of cell death pathways in BLCA was evaluated. Consensus clustering was performed based on identified PANoptosis genes. Cell death pathway scores, molecular, and… More >

  • Open Access

    ARTICLE

    Comprehensive molecular characterization to predict immunotherapy response in advanced biliary tract cancer: a phase II trial of pembrolizumab

    RYUL KIM1,#, JOO KYUNG PARK2,#, MINSUK KWON3, MINAE AN4, JUNG YONG HONG1, JOON OH PARK1, SUNG HEE LIM1,*, SEUNG TAE KIM1,*

    Oncology Research, Vol.33, No.1, pp. 57-65, 2025, DOI:10.32604/or.2024.049054 - 20 December 2024

    Abstract Background: Immune checkpoint inhibitors (ICIs) are effective in a subset of patients with metastatic solid tumors. However, the patients who would benefit most from ICIs in biliary tract cancer (BTC) are still controversial. Materials and methods: We molecularly characterized tissues and blood from 32 patients with metastatic BTC treated with the ICI pembrolizumab as second-line therapy. Results: All patients had microsatellite stable (MSS) type tumors. Three of the 32 patients achieved partial response (PR), with an objective response rate (ORR) of 9.4% (95% confidence interval [CI], 2.0–25.2) and nine showed stable disease (SD), exhibiting a disease… More >

  • Open Access

    ARTICLE

    A prognosis model for predicting immunotherapy response of esophageal cancer based on oxidative stress-related signatures

    JING GUO1, CHANGYONG TONG1, JIANGUANG SHI1, XINJIAN LI1, XUEQIN CHEN2,*

    Oncology Research, Vol.32, No.1, pp. 199-212, 2024, DOI:10.32604/or.2023.030969 - 15 November 2023

    Abstract Oxidative stress (OS) is intimately associated with tumorigenesis and has been considered a potential therapeutic strategy. However, the OS-associated therapeutic target for esophageal squamous cell carcinoma (ESCC) remains unconfirmed. In our study, gene expression data of ESCC and clinical information from public databases were downloaded. Through LASSO-Cox regression analysis, a risk score (RS) signature map of prognosis was constructed and performed external verification with the GSE53625 cohort. The ESTIMATE, xCell, CIBERSORT, TIMER, and ImmuCellAI algorithms were employed to analyze infiltrating immune cells and generate an immune microenvironment (IM). Afterward, functional enrichment analysis clarified the underlying… More >

  • Open Access

    ARTICLE

    Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data

    XUEFENG WANG1,#, SICONG JIANG2,#, XINHONG ZHOU3, XIAOFENG WANG4, LAN LI5, JIANJUN TANG1,*

    Oncology Research, Vol.31, No.5, pp. 697-714, 2023, DOI:10.32604/or.2023.029458 - 21 July 2023

    Abstract Background: Pancreatic cancer is associated with high mortality and is one of the most aggressive of malignancies, but studies have not fully evaluated its molecular subtypes, prognosis and response to immunotherapy of different subtypes. The purpose of this study was to explore the molecular subtypes and the key genes associated with the prognosis of pancreas cancer patients and study the clinical phenotype, prognosis and response to immunotherapy using single-cell seq data and bulk RNA seq data, and data retrieved from GEO and TCGA databases. Methods: Single-cell seq data and bioinformatics methods were used in this… More >

  • Open Access

    ARTICLE

    PD-1 Relevant Genes Predict the Prognosis of Breast Cancer and Their Prediction Effect in Tumor Response to Immunotherapy

    Yu Xiao1,2,#, Jianping Jiang3,#, Yan Chen1,4, Yi Huang1, Changyuan Wei1,*

    Oncologie, Vol.24, No.4, pp. 729-742, 2022, DOI:10.32604/oncologie.2022.026118 - 31 December 2022

    Abstract Background: Immunotherapy is becoming a powerful approach in the treatment of breast cancer. However, high response rates in the majority of breast cancer patients have yet to be achieved. Materials and Methods: Based on public data sources, we identified 22 genes that are correlated with PD-1 expression as well as differentially expressed between tumor tissues and normal tissues, and high expression of all the key genes was correlated with a superior survival outcome. Using the least absolute shrinkage and selection operator Cox regression model, a risk score was constructed. Results: A multivariate Cox analysis showed that the… More >

Displaying 1-10 on page 1 of 7. Per Page